Contact
searchSearch
HMP Global
Login

May 2018 (Supplement)

From the Field
Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program
06/08/2018
Jonathan Gerber, MD; Zainab Shahi; Saad Z. Usmani, MD, FACP; Michael R. Grunwald, MD; Jigar Trivedi, MS, PharmD, BCOP; Tammy Cogdill, MSN, ANP-BC, OCN; Nilanjan Ghosh, MD, PhD; Belinda R. Avalos, MD; Dragos Plesca, PharmD, PhD, BCOP; Manisha Bhutani, MD, PhD
To read the full article, click here.
To read the full article, click here.
To...
06/08/2018
Journal of Clinical Pathways
Perspectives
The Evolution of Care for Acute Myeloid Leukemia and the Challenges of Defining Value
05/21/2018
William J. Cardarelli, PharmD
Abstract: Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Distinct subtypes of AML have been defined based on morphology, immunophenotyping, and molecular genetics. AML usually...
Abstract: Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow. Distinct subtypes of AML have been defined based on morphology, immunophenotyping, and molecular genetics. AML usually...
...
05/21/2018
Journal of Clinical Pathways
Department
How Novel Agents Are Likely to Be Incorporated Into Clinical Pathways for Acute Myeloid Leukemia
05/21/2018
Last year, the Food and Drug Administration (FDA) approved a total of 46 drugs, tying a record set for approvals in 2015. Cancer medications accounted for the majority of these approvals, with 16 oncology and 11...
Last year, the Food and Drug Administration (FDA) approved a total of 46 drugs, tying a record set for approvals in 2015. Cancer medications accounted for the majority of these approvals, with 16 oncology and 11...
Last...
05/21/2018
Journal of Clinical Pathways
Research in Review
Acute Myeloid Leukemia Research Highlights
05/21/2018
Clearance of Somatic Mutations and the Effect on Risk of Relapse in AML Clearance of somatic mutation at complete remission is associated with significantly better survival in patients with acute myeloid...
Clearance of Somatic Mutations and the Effect on Risk of Relapse in AML Clearance of somatic mutation at complete remission is associated with significantly better survival in patients with acute myeloid...
...
05/21/2018
Journal of Clinical Pathways
Editor's Page
Implications of the Changing Landscape in Acute Myeloid Leukemia for Clinical Pathways
05/21/2018
Winston Wong, PharmD
Acute myelogenous leukemia (AML) is a rapid progressing malignancy of the myeloid progenitor cells, characterized by an uncontrolled proliferation of primitive blast cells replacing normal bone marrow cells. It is...
Acute myelogenous leukemia (AML) is a rapid progressing malignancy of the myeloid progenitor cells, characterized by an uncontrolled proliferation of primitive blast cells replacing normal bone marrow cells. It is...
Acute...
05/21/2018
Journal of Clinical Pathways
JCP July-Aug Cover 2025

Current Issue

August 2025
Volume 11
Issue 4
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Volume 4

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use